Literature DB >> 20541036

What made sesquiterpene lactones reach cancer clinical trials?

Akram Ghantous1, Hala Gali-Muhtasib, Heikki Vuorela, Najat A Saliba, Nadine Darwiche.   

Abstract

Sesquiterpene lactones (SLs) are plant-derived compounds often used in traditional medicine against inflammation and cancer. This review focuses on the chemical and biological properties of SLs that lead to enhanced anticancer and anti-inflammatory effects. The chemical properties comprise alkylating center reactivity, lipophilicity, and molecular geometry and electronic features. SLs in clinical trials are artemisinin, thapsigargin and parthenolide and many of their synthetic derivatives. These drugs are selective toward tumor and cancer stem cells by targeting specific signaling pathways, which make them lead compounds in cancer clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541036     DOI: 10.1016/j.drudis.2010.06.002

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  140 in total

1.  NF-κB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer.

Authors:  Rong Hu; Anni Warri; Lu Jin; Alan Zwart; Rebecca B Riggins; Hong-Bin Fang; Robert Clarke
Journal:  Mol Cell Biol       Date:  2014-11-03       Impact factor: 4.272

2.  Effect of sesquiterpene lactone coronopilin on leukaemia cell population growth, cell type-specific induction of apoptosis and mitotic catastrophe.

Authors:  R Cotugno; R Fortunato; A Santoro; D Gallotta; A Braca; N De Tommasi; M A Belisario
Journal:  Cell Prolif       Date:  2011-12-14       Impact factor: 6.831

3.  Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.

Authors:  Vikas Tyagi; Hanan Alwaseem; Kristen M O'Dwyer; Jessica Ponder; Qi Ying Li; Craig T Jordan; Rudi Fasan
Journal:  Bioorg Med Chem       Date:  2016-06-16       Impact factor: 3.641

4.  Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.

Authors:  Joshua N Kolev; Kristen M O'Dwyer; Craig T Jordan; Rudi Fasan
Journal:  ACS Chem Biol       Date:  2013-11-08       Impact factor: 5.100

Review 5.  Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones.

Authors:  Yulin Ren; Jianhua Yu; A Douglas Kinghorn
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  Phenolics and eudesmanolide from aged common sage exudate with sugar.

Authors:  Tae Yeon Kim; Jeong-Yong Cho; Yu Geon Lee; Hang Yeon Jeong; Hyoung Jae Lee; Jae-Hak Moon
Journal:  Food Sci Biotechnol       Date:  2017-12-12       Impact factor: 2.391

7.  Induction of Apoptosis in Human Breast Cancer MCF-7 Cells by a Semi-Synthetic Derivative of Artemisinin: A Caspase-Related Mechanism.

Authors:  Leila Jamalzadeh; Hossein Ghafoori; Mahmoodreza Aghamaali; Reyhaneh Sariri
Journal:  Iran J Biotechnol       Date:  2017-09-27       Impact factor: 1.671

8.  Discovery of Small Molecules That Induce Lysosomal Cell Death in Cancer Cell Lines Using an Image-Based Screening Platform.

Authors:  Romina J Pagliero; Diego S D'Astolfo; Daphne Lelieveld; Riyona D Pratiwi; Sonja Aits; Marja Jaattela; Nathaniel I Martin; Judith Klumperman; David A Egan
Journal:  Assay Drug Dev Technol       Date:  2016-09-22       Impact factor: 1.738

Review 9.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

10.  Selective cytotoxicity, inhibition of cell cycle progression, and induction of apoptosis in human breast cancer cells by sesquiterpenoids from Inula lineariifolia Turcz.

Authors:  Jiang-Jiang Qin; Hui-Zi Jin; Ying Huang; Shou-De Zhang; Lei Shan; Sukesh Voruganti; Subhasree Nag; Wei Wang; Wei-Dong Zhang; Ruiwen Zhang
Journal:  Eur J Med Chem       Date:  2013-08-11       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.